News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Sacituzumab govitecan with or without pembrolizumab in TNBC
Photo from Dana-Farber’s Breast Oncology Center/X
Jun 25, 2024, 13:37

Sacituzumab govitecan with or without pembrolizumab in TNBC

The Dana-Farber’s Breast Oncology Center shared on X:

“Dana-Farber’s Breast Oncology Center is leading a study for metastatic triple-negative (TNBC) that is PD-L1-negative offering sacituzumab govitecan with or without pembrolizumab.

For more info call 877-338-7425 or visit here.”

Source: Dana-Farber’s Breast Oncology Center/X

cancer Dana-Farber’s Breast Oncology Center Metastatic Triple Negative Breast Cancer OncoDaily Oncology pembrolizumab Sacituzumab govitecan TNBC
Special Coverage
Opinion
May 4, 2025, 11:29
STELLAR II trial at ESTRO 2025: Immunotherapy Combined with Radiotherapy and Chemotherapy Reduces the Need for Surgery in Locally Advanced Rectal Cancer
Blog
May 4, 2025, 11:26
Collaboration between National Societies and Patients can Strengthen Advocacy - ESTRO
Blog
May 4, 2025, 11:14
Marie-Catherine Vozenin Honored with Claudius Regaud Award at ESTRO 2025
Blog
May 4, 2025, 11:13
Princess Dina Mired: A true trailblazer in Pediatric Oncology by Carlos Rodriguez-Galindo
Blog
May 4, 2025, 11:11
Ina Jürgenliemk-Schulz Receives Iridium 192 Award at ESTRO 2025
Societies
May 4, 2025, 11:03
ASCO Urges Lawmakers to Protect Federal Funding for Cancer Research and Prevention
Blog
May 4, 2025, 10:59
Sarah Barrett: A great and busy start to ESTRO25
Blog
May 4, 2025, 10:57
Joanna Metzner-Sadurski: Proud of Ruiling Yuan for Moderating 2025 COP Webinar on Oncology Advocacy
Blog
May 4, 2025, 10:46
Theresa O Donovan: RTTs Experiences and Perceptions of Providing Support to Patients with Acute Psychosocial Distress
Blog
May 4, 2025, 10:39
Andrew Loblaw: 20 year Data Propensity-based analysis of LDR vs HDR boost
Blog
May 4, 2025, 10:29
Enar Recalde: Radiotherapy for Merkel cell carcinoma at ESTRO2025
Blog
May 4, 2025, 10:21
Piet Ost: Can Durvalumab and SBRT improve outcomes in Oligorecurrent Prostate Cancer?